{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:30:19Z","timestamp":1761964219987},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.leukres.2009.04.036","type":"journal-article","created":{"date-parts":[[2009,5,30]],"date-time":"2009-05-30T08:39:23Z","timestamp":1243672763000},"page":"143-147","source":"Crossref","is-referenced-by-count":28,"title":["Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib"],"prefix":"10.1016","volume":"34","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Paola","family":"Iori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Colaci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Latagliata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausto","family":"Castagnetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni Fernando","family":"Torelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Usai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Valle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianantonio","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Fo\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2009.04.036_bib1","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/1078-0432.CCR-06-2147","article-title":"Important therapeutic targets in chronic myelogenous leukaemia","volume":"13","author":"Kantarjian","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2009.04.036_bib2","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood-2007-04-038943","article-title":"How I treat chronic myeloid leukaemia in the imatinib era","volume":"110","author":"Goldman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.04.036_bib3","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2009.04.036_bib4","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1517\/13543784.17.6.865","article-title":"New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check","volume":"17","author":"O\u2019Hare","year":"2008","journal-title":"Export Opin Investig Drugs"},{"key":"10.1016\/j.leukres.2009.04.036_bib5","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-07-5015","article-title":"Nilotinib","volume":"14","author":"Deininger","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2009.04.036_bib6","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.04.036_bib7","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.clinthera.2007.11.005","article-title":"Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"29","author":"Steinberg","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.leukres.2009.04.036_bib8","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/sj.leu.2402808","article-title":"Imatinib mesylate in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias","volume":"17","author":"Shimoni","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2009.04.036_bib9","first-page":"452","article-title":"The effect of prior exposure to imatinib on transplant-related mortality","volume":"91","author":"Deininger","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2009.04.036_bib10","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cncr.22778","article-title":"Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukaemia","volume":"110","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"issue":"July","key":"10.1016\/j.leukres.2009.04.036_bib11","author":"Shimoni","year":"2008","journal-title":"Leukemia 2008"},{"key":"10.1016\/j.leukres.2009.04.036_bib12","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1373\/clinchem.2004.031112","article-title":"European LeukemiaNet-6th Framework Program of the European Community denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to imatinib","volume":"50","author":"Soverini","year":"2004","journal-title":"Clin Chem"},{"key":"10.1016\/j.leukres.2009.04.036_bib13","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.04.036_bib14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.04.036_bib15","first-page":"825","article-title":"1994 Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.leukres.2009.04.036_bib16","first-page":"1517","article-title":"An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology","volume":"94","author":"Silver","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.04.036_bib17","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2008-02-141689","article-title":"Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia","volume":"112","author":"Lee","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.04.036_bib18","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.exphem.2008.05.002","article-title":"Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukaemia antigens","volume":"36","author":"Fei","year":"2008","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2009.04.036_bib19","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1200\/JCO.2003.05.108","article-title":"New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors","volume":"21","author":"Baker","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609002446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609002446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T07:51:20Z","timestamp":1545205880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212609002446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0145212609002446"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2009.04.036","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}